Major Sponsor:




Contributing Sponsors:













Login Form






Lost Password?
No account yet? Register
Grand Rounds in Urology, Volume 7, Issue 5

GRU Volume 7, Issue 5

NEEDS ASSESSMENT

Over the last two decades there has been a growing awareness of the impact of testosterone deficiency (TD), also called hypogonadism, on men’s health. Though the condition of TD was once associated primarily with obvious and severe medical conditions, today we recognize that TD affects a large number of otherwise healthy adults, and is particularly prevalent among men with common chronic medical conditions such as diabetes, obesity, and chronic pulmonary disease. Another emerging concept is that TD affects much more than sexuality. TD has been shown to be associated with impaired mood, sense of vitality, diminished energy, chronic fatigue, loss of muscle mass, truncal obesity, the metabolic syndrome, and osteoporosis.

Although many of the issues associated with TD relate to general medicine, the urologist has an important role in the diagnosis and treatment of TD. Since the sexual symptoms are often the presenting symptoms that drive the patient to seek medical attention, the urologist is often the first person with an opportunity to diagnose the condition. As the specialist most closely involved with male-specific health issues, it is important for the urologist to become familiar with current evidence regarding the impact of TD on men’s health. In this issue, authors will review the various signs and symptoms of TD, who is a candidate for treatment, considerations in choosing forms of testosterone therapy, the risks of treatment, and how to monitor the man receiving testosterone therapy.

Read more...
 
Grand Rounds in Urology, Volume 7, Issue 4

GRU Volume 7, Issue 4

PURPOSE STATEMENT

The purpose of this educational activity is to increase the knowledge of physicians with a review of the recent update on the management on non-muscle invasive bladder cancer as well as information on ongoing and future treatment options.

NEEDS ASSESSMENT

More than 60,000 new cases of bladder cancer are diagnosed each year in the United States, accounting for approximately 13,000 deaths annually [1]. Most of these cancers do not deeply invade the bladder muscle and may be successfully treated by a variety ofregimens. In 1999, the American Urological Association (AUA) published the Report on the Management of Non-Muscle-Invasive Bladder cancer (Stages Ta, T1, and Tis), produced by the AUA’s Bladder Cancer Clinical Guideline Panel [2]. The report provided an evidence-based guideline for the management of patients with non-muscle-invasive bladder cancer. Much has changed since 1999, andthe AUA Practice Guidelines Committee decided that it was time to update the initial report. The recently completed revision, which is en- titled Guideline for the Management of Non- muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update, includes current information on epidemiology, risk stratification, tumor markers, modes of therapy, and bladder cancer characteristics [3]. It is important for physicians to become aware of this recent update and to become aware of the current status of treatment options for bladder cancer. There are currently 312 ongoing clinical trials involving the diagnosis and treatment of bladder cancer [4].
Read more...
 
Grand Rounds in Urology, Volume 7, Issue 3

 

GRU Volume 7, Issue 3


Hypogonadism affects several million men in the United States, its prevalence increases with age, and it is underdiagnosed and undertreated. Reasons for underdiagnosis and undertreatment are numerous. First, signs and symptoms of low testosterone are often subtle and nonspecific. Second, a consensus on the definition of low testosterone has not been established. Many commercially available assays for the measurement of testosterone levels have not been standardized, resulting in considerable variability among laboratories in reference values for identifying low testosterone levels.

Read more...
 
Treatment of Superficial Bladder Cancer
Don Lamm, MD, FACS

Don Lamm, MD, FACS, Director, BCG Oncology Clinical Professor, University of Arizona, Phoenix, Arizona, presented a lecture at the New Technologies and Innovative Treatment Strategies for Genitourinary Malignancies meeting, held September 28-30, 2007, in San Diego. The program is intended for healthcare specialists involved in diagnosing and treating genitourinary diseases.

View the lecture
 
<< Start < Prev 1 2 Next > End >>

Results 1 - 5 of 6